Edgewise Therapeutics, Inc.
EWTX$1.40B
Small CapNASDAQPharmaceutical Preparations🇺🇸North AmericaBOULDER136 employees
Drugs in Pipeline
4
Phase 3 Programs
0
Upcoming Catalysts
3
Next Catalyst
Jun 15, 2026
16wMarket Overview
Stock performance and key metrics
EWTX News
Catalyst Timeline
3 upcoming, 0 past
Drug Pipeline
EDG-7500
Hypertrophic Cardiomyopathy
Sevasemten 10 mg
Becker Muscular Dystrophy
Sevasemten Dose 1
Duchenne Muscular Dystrophy
Sevasemten Dose 2
Duchenne Muscular Dystrophy
| Drug Name | Phase | Indication | Designations |
|---|---|---|---|
EDG-7500 | Phase 2 | Hypertrophic Cardiomyopathy | - |
Sevasemten 10 mg | Phase 2 | Becker Muscular Dystrophy | - |
Sevasemten Dose 1 | Phase 2 | Duchenne Muscular Dystrophy | - |
Sevasemten Dose 2 | Phase 2 | Duchenne Muscular Dystrophy | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply